Advances in Magnetic Resonance Imaging and Positron Emission Tomography Imaging for Grading and Molecular Characterization of Glioma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26050586.
- Also identified by DOI 10.1016/j.semradonc.2015.02.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In recent years, the management of glioma has evolved significantly, reflecting our better understanding of the underlying mechanisms of tumor development, tumor progression, and treatment response. Glioma grade, along with a number of underlying molecular and genetic biomarkers, has been recognized as an important prognostic and predictive factor that can help guide the management of patients. This article highlights advances in magnetic resonance imaging (MRI), including diffusion-weighted imaging, diffusion tensor imaging, magnetic resonance spectroscopy, dynamic contrast-enhanced imaging, and perfusion MRI, as well as position emission tomography using various tracers including methyl-(11)C-l-methionine and O-(2-(18)F-fluoroethyl)-l-tyrosine. Use of multiparametric imaging data has improved the diagnostic strength of imaging, introduced the potential to noninvasively interrogate underlying molecular features of low-grade glioma and to guide local therapies such as surgery and radiotherapy.
Medical subject headings
- Brain Neoplasms
- Glioma
- Magnetic Resonance Imaging
- Positron-Emission Tomography